Development and efficacy of NXY-059 for the treatment of acute ischemic stroke

Future Neurology

Volumn 3, Issue 3, 2008, Pages 229-240

  Papadakis, Michalis ^a   Nagel, Simon ^a,b   Buchan, Alastair M ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cerovive ; Free radical scavenger; Ischemia; Neuroprotection; NXY 059; Stroke

Indexed keywords

ALBUMIN; ALTEPLASE; ANTITHROMBOCYTIC AGENT; DEFEROXAMINE; DESMOTEPLASE; DISUFENTON SODIUM; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FIBRINOLYTIC THERAPY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; INDUCED HYPOTHERMIA; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RANKIN SCALE; STEADY STATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 44149126999     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.3.229     Document Type: Article

References (39)

1. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E: Thrombolysis for acute ischaemic stroke. Cochrane Database Syst. Rev. 3, CD000213 (2003).
2. O'Collins VE, Macleod MR, Dorman GA et al.: 1,026 experimental treatments in acute stroke. Ann. Neurol. 59(3), 467-477 (2006).
3. Lees KR, Zivin JA, Ashwood T et al.: NXY-059 for acute ischemic stroke. N. Engl. J. Med 354(6), 588-600 (2006).
4. Shuaib A, Lees KR, Lyden P et al.: NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 357(6), 562-571 (2007).
5. Floyd RA, Hensley K, Forster MJ, Kelleher-Anderson JA, Wood PL: Nitrones as ncuroprotectants and antiaging drugs. Ann. NY Acad Sci. 959, 321-329 (2002).
6. Shi H, Liu KJ: Cerebral tissue oxygenation and oxidative brain injury during ischemia. and reperfusion. Front. Biosci. 12, 1318-1328 (2007).
7. Ginsberg MD, Palesch YY, Hill MD: The Albumin in Acute Stroke (ALIAS) Phase III randomized multicenter clinical trial: design and progress report. Biochem. Soc. Trans. 34, 1323-1326 (2006).
8. Bernard SA, Gray TW, Buist MD et al.: Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N. Engl. J. Med. 346(8), 557-563 (2002).
9. NINDS t-PA trial: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333(24), 1581-1587 (1995).
10. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM: A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 36(3), 607-612 (2005).
11. Hacke W, Albers G, Al Rawi Y et al.: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36(1), 66-73 (2005).
12. Furlan AJ, Eyding D, Albers GW et al.: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37(5), 1227-1231 (2006).
13. Mayer SA, Brun NC, Begtrup K et al.: Recombinant activated factor VII for acute intracerebral hemorrhage. N. Engl. J. Med. 352(8), 777-785 (2005).
14. Mayer SA, Brun NC, Begtrup K et al.: Randomized, placebo-controlled, double-blind Phase III study to assess rFVIIa efficacy in acute intracerebral hemorrhage: the FAST trial. European Stroke Conference. May 29-June 1, Glasgow, UK (2007).
15. STAIR: Stroke Therapy Academic Industry Roundtable: recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30(12), 2752-2758 (1999).
16. STAIR II: Stroke Therapy Academic Industry Roundtable II: recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32, 1598-1606 (2001).
17. Fisher M: Stroke Therapy Academic Industry Roundtable. Recommendations for advancing development of acute stroke therapies Stroke Therapy Academic Industry Roundtable 3. Stroke 34, 1539-1546 (2003).
18. Maples KR, Ma F, Zhang YK: Comparison of the radical trapping ability of PBN, S-PBN and NXY-059. Free Rad. Res. 34, 417-426 (2001).
19. Green AR, Ashwood T, Odergren T, Jackson DM: Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol. Ther. 100(3), 195-214 (2003).
20. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK: Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab. 19(70), 778-787 (1999).
21. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM: NXY-059, a novel free radical trapping compound, reduced cortical infarction after permanent focal ischemia in the rat. Brain Res. 909, 46-50 (2001).
22. Sydserff SG, Borelli AR, Green AR, Cross AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol. 135(1), 103-112 (2002).
23. Marshall JW, Duffin KJ, Green AR, Ridley RM: NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 32(1), 190-198 (2001).
24. Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR: Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 34(9), 2228-2233 (2003).
25. Marshall JW, Green AR, Ridley RM: Comparison of the neuroprotective effect of clomethiazole, AR-R1589AR and NXY-059 in a primate model of stroke using histological and behavioural measures. Brain Res. 972, 119-126 (2003).
26. Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM: Efficacy of disodium 4-([tert-butylimino]methyl) benzene- 1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacol. 40(3), 433-439 (2001).
27. Dehouck MP, Cecchelli P, Richard GA, Renftel M, Lundquist S: In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective rutrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. Brain Res. 955(1-2), 229-235 (2002).
28. Green AR, Lanbeck-Vallen K, Ashwood T et al.: Brain penetration of the novel ftee radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia. Brain Res. 1072(1), 224-226 (2006).
29. Hainsworth AH, Bhuiyan N, Green AR: The nitorne disodium 2,4-sulphophenyl-N-tert-butylnitrone is without cytoprotective effect on sodium nitropursside-induced cell death in N1E-115 neuroblastoma cells in vitro. J. Cereb. Blood Flow Metab. 28, 24-28 (2008).
30. Edenius C, Strid S, Borga O et al.: Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects. J. Stroke Cerebrovasc. Dis. 11, 34-43 (2002).
31. Strid S, Borga O, Edenius C, Jostell KG, Odergren T, Weil A: Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Eur. J. Clin. Pharmacol. 58, 409-415 (2001).
32. Lees KR, Sharma AK, Barer D et al.: Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 32(3), 675-680 (2001).
33. Lees KR, Barer D, Ford GA et al.: Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 34(2), 482-487 (2003).
34. Lees KR, Davalos A, Davis SM et al.: Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. Stroke 37(12), 2970-2978 (2006).
35. Koziol JA. Feng AC: On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY'059 for acute ischemic stroke. Stroke 37, 2644-2647 (2006).
36. Dirnagl U: Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab. 26(12), 1465-1478 (2006).
37. Donnan GA. The 2007 Feinberg lecture: a new road map for neuroprotection. Stroke 39(1), 242-248 (2008).
38. Ransom BR, Fern R: Does astrocytic glycogen benefit axon function and survival in CNS white matter during glucose deprivation? Glia 997(21), 134-141 (1997).
39. Papadakis M, Buchan AM: NXY-059: brain or vessel protection. Stroke 37(8), 2189-2190 (2006).